Link
Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 vaccination
Organization: Canadian Paediatric Society (CPS)Published: 2021
"This practice point aims to provide clinical guidance on myocarditis and pericarditis following mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). The benefits of COVID-19 vaccination outweigh the risks, and the vaccine is recommended for all eligible individuals, including children and youth in their 12th year and over. A small increased risk of myocarditis and pericarditis (< 1 case per 10,000) has been reported following vaccination with COVID-19 mRNA vaccines in Canada and internationally, most often among adolescents and young adults < 30 years of age, males, and after the second dose. Although this safety signal is occurring at higher-than-expected background rates, most cases are mild. This document reflects expert opinion and available evidence, which is limited." - Clinical guidance for youth with myocarditis and pericarditis following mRNA COVID-19 vaccination
Product Type: Guide
Category:
Vaccine Safety and Development,Vaccine Safety,Adverse Events Following Immunization (AEFI),Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and DevelopmentVaccine Safety
Adverse Events Following Immunization (AEFI)
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.